{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:56:24Z","timestamp":1787500584057,"version":"build-2736575974"},"reference-count":90,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2624971","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:12:09Z","timestamp":1772723529000},"page":"547-562","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness of exagamglogene autotemcel gene-edited therapy in patients with sickle cell disease with recurrent vaso-occlusive crises in the United States"],"prefix":"10.1080","volume":"29","author":[{"given":"Andrea","family":"Lopez","sequence":"first","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gargano","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foluso Joy","family":"Ogunsile","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham","place":["Birmingham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanxin","family":"Li","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwen","family":"Xie","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Los Angeles, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushanth","family":"Jeyakumar","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuka","family":"Udeze","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)30193-9"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.10"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510865"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2020.08.009"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(23)00118-7"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-189287"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.36469\/9667"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-03074-z"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13430"},{"issue":"5","key":"e_1_3_5_11_1","first-page":"1349","article-title":"Approach to the vaso-occlusive crisis in adults with sickle cell disease","volume":"61","author":"Yale SH","year":"2000","unstructured":"Yale SH, Nagib N, Guthrie T. Approach to the vaso-occlusive crisis in adults with sickle cell disease. Am Fam Physician. 2000;61(5):1349\u20131356.","journal-title":"Am Fam Physician"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2010.1.409"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02545-7"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.09.444"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157818"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26063"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-019-02412-5"},{"key":"e_1_3_5_18_1","volume-title":"Guidelines for the management of transfusion-dependent thalassaemia","author":"Thalassaemia International Federation","year":"2021","unstructured":"Thalassaemia International Federation. Guidelines for the management of transfusion-dependent thalassaemia. 4th ed.; 2021. https:\/\/issuu.com\/internationalthalassaemiafederation\/docs\/final_guideline_4th. Accessed July 1, 2023."},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.31486\/toj.18.0076"},{"key":"e_1_3_5_20_1","volume-title":"CASGEVY\u2122 (exagamglogene autotemcel), suspension for intravenous infusion prescribing information","author":"Vertex Pharmaceuticals Incorporated","year":"2024","unstructured":"Vertex Pharmaceuticals Incorporated. CASGEVY\u2122 (exagamglogene autotemcel), suspension for intravenous infusion prescribing information. Boston, MA; Vertex Pharmaceuticals Incorporated. 2024. https:\/\/pi.vrtx.com\/files\/uspi_exagamglogene_autotemcel.pdf"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309676"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a011643"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.4103\/ajts.AJTS_71_16"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2022.2066519"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-528067"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113782"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007645"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204001"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-190203"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12454577"},{"key":"e_1_3_5_31_1","volume-title":"Gene therapies for sickle cell disease: effectiveness and value; evidence report","author":"Beaudoin F","year":"2023","unstructured":"Beaudoin F, Thokala P, Nikitin D, et al. Gene therapies for sickle cell disease: effectiveness and value; evidence report. Boston: Institute for Clinical and Economic Review; 2023."},{"key":"e_1_3_5_32_1","first-page":"23","volume-title":"Crizanlizumab, voxelotor, and L-glutamine for sickle cell disease: effectiveness and value","author":"Bradt P","year":"2020","unstructured":"Bradt P, Spackman E, Synnott P, et al. Crizanlizumab, voxelotor, and L-glutamine for sickle cell disease: effectiveness and value. Boston: Institute for Clinical and Economic Review; 2020. p. 23."},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.731102"},{"key":"e_1_3_5_34_1","unstructured":"NICE. Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia. Committee Papers. National Institute for Health and Care Excellence. 2022 https:\/\/www.nice.org.uk\/guidance\/gid-ta10334\/documents\/committee-papers"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dew123"},{"key":"e_1_3_5_36_1","unstructured":"American Society for Reproductive Medicine. Age and fertility;. 2022 https:\/\/www.reproductivefacts.org\/news-and-publications\/fact-sheets-and-infographics\/age-and-fertility-booklet\/"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611770"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903212"},{"key":"e_1_3_5_39_1","volume-title":"Oral L-glutamine powder for the treatment of sickle cell disease. NDA 208587","author":"Sponsor Briefing Document","year":"2023","unstructured":"Sponsor Briefing Document. Oral L-glutamine powder for the treatment of sickle cell disease. NDA 208587. Silver Spring, MD: Food and Drug Administration; 2023. https:\/\/www.fda.gov\/media\/105731\/download"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2024.09.023"},{"key":"e_1_3_5_41_1","volume-title":"NICE clinical guideline 143: sickle cell acute painful episode (appendix F)","author":"NICE","year":"2023","unstructured":"NICE. NICE clinical guideline 143: sickle cell acute painful episode (appendix F). London: National Institute for Health and Clinical Excellence; 2023. https:\/\/www.nice.org.uk\/guidance\/cg143\/evidence\/appendix-f-full-health-economic-report-pdf-186634334"},{"key":"e_1_3_5_42_1","volume-title":"Life tables for males and females: United States","author":"National Vital Statistics System, Mortality","year":"2022","unstructured":"National Vital Statistics System, Mortality. Life tables for males and females: United States. Hyattsville, MD: National Center for Health Statistics. 2022. https:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr70\/nvsr70-1-508.pdf."},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04233-w"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-020-02650-y"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-019-01136-0"},{"key":"e_1_3_5_46_1","volume-title":"Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]","author":"NICE","year":"2022","unstructured":"NICE. Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]. London: National Institute for Health and Care Excellence; 2022. https:\/\/www.nice.org.uk\/guidance\/ta743\/documents\/committee-papers"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.3132\/pcrj.2007.00002"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.08.002"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223043"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4733.2001.40202-165.x"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.6786"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2006.11.009"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta16430"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0000000000000262"},{"key":"e_1_3_5_55_1","unstructured":"NICE. Guidelines: gallstone disease: diagnosis and management of cholelithiasis cholecystitis and choledocholithiasis. National Institute for Health and Care Excellence; 2023 https:\/\/www.nice.org.uk\/guidance\/cg188."},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12978-019-0706-9"},{"key":"e_1_3_5_57_1","first-page":"365","article-title":"CTX001 for sickle cell disease: safety and efficacy results from the ongoing climb SCD-121 study of autologous CRISPR-Cas9-modified CD34+ hematopoietic stem and progenitor cells","volume":"5","author":"Grupp S","year":"2021","unstructured":"Grupp S, Bloberger N, Campbell C, et al. CTX001 for sickle cell disease: safety and efficacy results from the ongoing climb SCD-121 study of autologous CRISPR-Cas9-modified CD34+ hematopoietic stem and progenitor cells. Hemasphere. 2021;5:365.","journal-title":"Hemasphere"},{"key":"e_1_3_5_58_1","volume-title":"Betibeglogene autotemcel for beta thalassemia: effectiveness and value; evidence report","author":"Beaudoin F","year":"2022","unstructured":"Beaudoin F, Richardson M, Synnott P. Betibeglogene autotemcel for beta thalassemia: effectiveness and value; evidence report. Boston: Institute for Clinical and Economic Review; 2022."},{"key":"e_1_3_5_59_1","unstructured":"Merative. Merative Micromedex\u00ae RED BOOK\u00ae; 2024 https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/"},{"key":"e_1_3_5_60_1","unstructured":"Centers for Medicare and Medicaid Services. CMS physician fee schedule; 2022. https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search."},{"key":"e_1_3_5_61_1","unstructured":"Centers for Medicare and Medicaid Services. Medicare inpatient hospitals - by provider and service dataset; 2023. https:\/\/data.cms.gov\/provider-summary-by-type-of-service\/medicare-inpatient-hospitals\/medicare-inpatient-hospitals-by-provider-and-service"},{"key":"e_1_3_5_62_1","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: DROXIA (hydroxyurea capsules); 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/016295s041s042lbl.pdf"},{"key":"e_1_3_5_63_1","volume-title":"Guidelines for the management of transfusion dependent thalassemia (TDT)","author":"Farmakis D","year":"2021","unstructured":"Farmakis D, Porter JTA, Cappellini MD. Guidelines for the management of transfusion dependent thalassemia (TDT). 4th ed. Nicosia: Thalassemia International Federation; 2021.","edition":"4"},{"key":"e_1_3_5_64_1","unstructured":"European Medicines Agency. Product information for Exjade (deferasirox); 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/exjade-epar-product-information_en.pdf"},{"key":"e_1_3_5_65_1","unstructured":"European Medicines Agency. Product information for Ferriprox (deferiprone); 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ferriprox-epar-product-information_en.pdf."},{"key":"e_1_3_5_66_1","volume-title":"DROXIA (hydroxyurea), capsules for oral use, prescribing information","author":"BMS","year":"2015","unstructured":"BMS. DROXIA (hydroxyurea), capsules for oral use, prescribing information. Princeton, NJ; Bristol-Myers Squibb Company; 2015. https:\/\/packageinserts.bms.com\/pi\/pi_droxia.pdf"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2012.07.025"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.9763"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.903258"},{"key":"e_1_3_5_70_1","volume-title":"The clinical and cost burden of an important consequence of osteoporosis","author":"Hansen D","year":"2019","unstructured":"Hansen D, Bazell C, Pelizzari P, et al. Medicare cost of osteoporotic fractures. In: The clinical and cost burden of an important consequence of osteoporosis. Seattle, WA: Milliman; 2019."},{"key":"e_1_3_5_71_1","unstructured":"Wittenborn JS Zhang X Feagan CW et al. Cost of vision problems: the economic burden of vision loss and eye disorders in the United States; 2023. https:\/\/preventblindness.org\/wp-content\/uploads\/2020\/04\/Economic-Burden-of-Vision-Final-Report_130611_0.pdf."},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.07.020"},{"key":"e_1_3_5_73_1","unstructured":"Alliance for Fertility Preservation. How much does fertility preservation cost?; 2023 https:\/\/www.allianceforfertilitypreservation.org\/paying-for-treatments\/"},{"key":"e_1_3_5_74_1","unstructured":"National Inpatient Sample. Healthcare cost and utilization project. 2015. https:\/\/hcup-us.ahrq.gov\/nisoverview.jsp"},{"key":"e_1_3_5_75_1","unstructured":"Centers for Medicare and Medicaid Services. CMS clinical laboratory fee schedule; 2022 https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/ClinicalLabFeeSched\/Clinical-Laboratory-Fee-Schedule-Files"},{"key":"e_1_3_5_76_1","unstructured":"United States Bureau of Economic Analysis. Price indexes for personal consumption expenditures by major type of product: Personal consumption expenditure (PCE) price index health care; 2022. https:\/\/apps.bea.gov\/iTable\/iTable.cfm?1921=underlying&isuri=1&reqid=19&step=2#1921=underlying&isuri=1&reqid=19&step=2"},{"key":"e_1_3_5_77_1","unstructured":"US Bureau of Labor Statistics. Table B-3: Average hourly and weekly earnings of all employees on private nonfarm payrolls by industry sector seasonally adjusted; 2022. https:\/\/www.bls.gov\/news.release\/empsit.toc.htm"},{"key":"e_1_3_5_78_1","unstructured":"US Bureau of Labor Statistics. Normal retirement age; 2022 https:\/\/www.ssa.gov\/oact\/progdata\/nra.html."},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.15374"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009202"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.09.544"},{"key":"e_1_3_5_82_1","volume-title":"Presented at: ISPOR Europe; Barcelona, Spain","author":"Udeze C","year":"2024","unstructured":"Udeze C, Gargano M, Kaindl L, et al. Model-Projected survival and lifetime clinical outcomes of exagamglogene autotemcel (exa-cel) in patients with sickle cell disease with recurrent vaso-occlusive crises in Canada. Presented at: ISPOR Europe; Barcelona, Spain; 2024."},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90405-1"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0079923"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1486703"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.03.014"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.02.001"},{"key":"e_1_3_5_88_1","volume-title":"LYFGENIA\u00ae (lovotibeglogene autotemcel) suspension for intravenous infusion prescribing information","author":"Bluebird Bio, Inc","year":"2025","unstructured":"Bluebird Bio, Inc. LYFGENIA\u00ae (lovotibeglogene autotemcel) suspension for intravenous infusion prescribing information. Somerville: Bluebird Bio, Inc; 2025. https:\/\/www.bluebirdbio.com\/-\/media\/bluebirdbio\/Corporate%20COM\/Files\/Lyfgenia\/LYFGENIA_Prescribing_Information.pdf"},{"key":"e_1_3_5_89_1","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: ENDARI (L-gluamine oralpowder). 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208587s003lbl.pdf"},{"key":"e_1_3_5_90_1","unstructured":"United States Food and Drug Administration. Highlights of prescribing informaton: ADAKVEO (crizanlizumab-tmca) injection. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761128s000lbl.pdf"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0253986"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2624971","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:12:17Z","timestamp":1772723537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2624971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2624971"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2624971","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-11-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}